Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel
NYSEAMERICAN:AZTR

Azitra Q3 2024 Earnings Report

Azitra logo
$0.18 -0.01 (-4.79%)
As of 08/28/2026 04:10 PM Eastern
ProfileEarnings HistoryForecast

Azitra EPS Results

Actual EPS
-$1.13
Consensus EPS
-$3.20
Beat/Miss
Beat by +$2.06
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Q3 2024
Date
11/12/2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Azitra's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Azitra's Q3 2024 Press ReleasePress Release
(8-K)
Azitra's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Azitra Earnings Headlines

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
August 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/azitra-inc-regains-compliance-with-nyse-american-continued-listing-standards-302856928.html
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
August 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/azitra-inc-announces-q2-2026-results-and-provides-business-updates-302850148.html
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
August 30 at 1:00 AM  |  Porter & Company (Ad)
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
July 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/azitra-inc-announces-breakthough-repeat-dose-and-anti-wrinkle-ex-vivo-results-for-atr-cosf-program-demonstrating-increased-distribution-and-elasticity-302826522.html
Azitra Expands Authorized Shares Following Stockholder Approvals
June 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AZTR/pressreleases/2514737/azitra-expands-authorized-shares-following-stockholder-approvals/
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
June 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/azitra-inc-ceo-issues-letter-to-shareholders-detailing-strategic-reorientation-initiatives-and-outlook-for-2026-and-beyond-302802341.html
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR) Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance. By delivering live commensal organisms directly to affected skin regions, Azitra seeks to restore healthy barrier function and reduce inflammation without relying on conventional small-molecule or biologic drug approaches.

Founded in 2018, Azitra is traded on the NYSE American under the symbol AZTR. Its research and development operations combine microbiology, formulation science and translational dermatology, and the company’s clinical trials are conducted primarily in North America. Azitra has pursued collaborations with academic and medical centers to support its pipeline advancement.

Azitra’s leadership team brings together expertise in microbiome research, dermatology and pharmaceutical development, guiding the company toward regulatory milestones and strategic partnerships. With a mission to harness the therapeutic potential of the skin microbiome, Azitra aims to offer novel, targeted treatments for patients with chronic skin diseases.

View Azitra Profile
Earnings Tools